Product Images Docetaxel

This text appears to be a graph or chart displaying survival probability and survival time. The survival probability is listed in percentages at various time intervals, including 24, 30, 3, 42, 48, 54, and 60 months. The survival time is only listed at 72 months. It is unclear what this data represents without additional context.*

Not-Available.*

This is a product description for a medication called Docetaxel, available as a one-vial formulation for intravenous infusion. The product information includes dosage guidelines (10-60 cents, 20-AH), the manufacturer's address, and NDC code (70121-1221-1). The label warns that this medication is cytotoxic and is for intravenous infusion only.*

This is a description of a medicine - Docetaxel Injection, USP which is used for intravenous infusion only. It is a single-dose vial and should only be added to an infusion solution. The usual dosage information is included in the package. The warning states that it is a cytotoxic agent and should be kept away from children. The content of the vial is 1 mL and should be stored at a temperature between 20°C and 25°C. The instructions also state to protect it from light. The lot number and expiration date are included on the packaging.*

This is a description for a pharmaceutical product. The text mentions "Docetaxel" in a solution of "Injection, USP" which is cytotoxic and for intravenous infusion only. It is a vial formulation with a concentration of 20 mg/mL and is ready to add to infusion solution. The National Drug Code (NDC) for this product is 70121-1222-1.*

This is a product description for a medication called Docetaxel Injection, USP. The medication is available in a one-vial formulation of 80mg/4mL (20mg/ml). The typical dosage instructions can be found on the package. It is distributed by Amneal Pharmaceuticals LLC and manufactured by Amneal Oncology Pvt. Ltd. The medication is to be used for intravenous infusion only and is labeled as a Cytotoxic agent. It should be stored between 20-25°C and protected from light.*

This is a description of a medication called Docetaxel Injection, USP, which is a cytotoxic drug used for intravenous infusion only. It comes in a 20mg/ml one-vial formulation that needs to be added to an infusion solution. Each ml contains 20mg docetaxel anhydrous, USP, and 0.4mg citric acid anhydrous in 50/50 (v/v) ratio of polysorbate 80/dehydrated alcohol. The usual dosage should be seen in the package insert. This medication is manufactured in India with Mfg. Lic. No. 7429/A3/2014 by Amneal Pharmaceuticals LLC located in Bridgewater, NJ 08807.*

This is a product description for Docetaxel Injection, USP. Each mL of the injection contains 20mg of docetaxel anhydrous, USP, and 0.4mg of polysorbate 80. The vial has a strength of 160mg/8mL. The injection is a cytotoxic agent that should be kept out of the reach of children and promptly discarded after single-use. It is intended for intravenous infusion only. The product should be stored in a cool, dark place between temperatures of 20° to 25°C (68° to 77°F). Lot number and expiration date information is provided on the packaging.*

This appears to be a table, with headings "OFS Probability" and "Disease-Free Survival Time" and some additional information in the table cells. However, the table is not complete and it is not clear what the values in the table cells represent without more context.*

This appears to be a graph or data table comparing survival probability and survival time, with percentages and months as the units of measurement. However, without further context or labels, it is difficult to interpret or draw any meaningful conclusions from this information.*

The text describes a graph or chart displaying survival time in months with cumulative probabilities. There is a logarithmic calculation with a resulting p value of 0.01. The time scale on the graph spans from 6 months to 21 months in increments of 3.*

This appears to be a graph showing the cumulative probability of survival over time (months) for an unknown subject or group. The x-axis shows the months, and the y-axis shows the cumulative probability of survival. There are also some labels and values in the graph, but it is unclear what they represent without further context.*

The text represents a graph displaying the probability of progression-free survival (PFS) in percentage at different time intervals in months (36 months) for a particular medical treatment. The PFS probability is shown to increase from 6% at 6 months to 30% at 36 months.*